Cardinal’s Syncor acquisition on hold
Executive Summary
"There can be no assurance that the transaction involving the acquisition of Syncor by Cardinal Health will be completed," the drug wholesaler said Nov. 6. Cardinal's due diligence investigation discovered "improper payments that had been made in foreign countries by subsidiaries of Syncor," the company said. Cardinal announced its merger agreement with the nuclear pharmacy company in June (1"The Pink Sheet" June 17, p. 9)...
You may also be interested in...
Cardinal’s Syncor acquisition
Cardinal will issue about 13 mil. shares to Syncor stockholders at a ratio of .47 Cardinal shares for each outstanding share of Syncor stock under amended merger agreement. Cardinal put a hold on the acquisition of the nuclear pharmacy company Nov. 6 after discovering Syncor subsidiaries had made improper payments in foreign countries (1"The Pink Sheet" Nov. 11, In Brief). Syncor reached agreements with the Department of Justice and the Securities & Exchange Commission to pay fines and civil penalties totaling $2.5 mil. The merger still has to be approved by Syncor stockholders...
Cardinal/Syncor try to save merger
Cardinal Health and Syncor begin merger re-negotiations following Syncor's announcement of potential "questionable payments" to customers in Taiwan and other countries (1"The Pink Sheet" Nov. 11, In Brief)...
Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor
Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor